SCHEMBL10258351

SCHEMBL10258351

CC1OC(c2cccc(N)c2)O1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.42
CASP1 P29466 2/20 0.42
RECQL P46063 1/20 0.42
ALDH1A1 P00352 6/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CA14 Q9ULX7 1/20 0.35
MAOA P21397 1/20 0.34
KDM4E B2RXH2 2/20 0.33
TP53 P04637 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
CASP7 P55210 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8054098 0.78 KMT2A (0.44) ALDH1A1MEN1MAPTALOX15KMT2A
SCHEMBL12841087 0.78 SLC5A2 (0.39) CYP3A4MAOAMEN1KMT2A
SCHEMBL12641997 0.76 KDM1A (0.44) CYP3A4ALDH1A1MEN1MAPTKMT2A
SCHEMBL12508616 0.76 SLC6A2 (0.31)
SCHEMBL12812849 0.76
SCHEMBL8342901 0.76 PNMT (0.41) CYP3A4ALDH1A1NOS1ENPP2
SCHEMBL7833417 0.75 CYP3A4 (0.46) CYP3A4CASP1RECQLALDH1A1DDB1
SCHEMBL8357649 0.74 MAPT (0.38) CYP3A4CASP1ALDH1A1TDP1CA14
SCHEMBL30439399 0.73 CYP3A4 (0.44) CYP3A4CASP1RECQLALDH1A1DDB1
SCHEMBL233910 0.73 CYP3A4 (0.44) CYP3A4CASP1RECQLALDH1A1DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129930-A1 KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. (US) 2012-05-24 US disclosed
US-7705177-B2 Ketone compounds and compositions for cholesterol management and related uses ESPERION THERAPUETICS, INC. (US) 2010-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129930-A1 KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES PC, HMGCR, CETP CYP3A4 435/4885CASP1 923/4885RECQL 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.